Literature DB >> 7612339

Women's use of hormone replacement therapy for relief of menopausal symptoms, for prevention of osteoporosis, and after hysterectomy.

F Griffiths1, B Convery.   

Abstract

BACKGROUND: Hormone replacement therapy is used for the relief of menopausal symptoms. In the United Kingdom, guidelines have been developed for the use of hormone replacement therapy in the prevention of osteoporosis, and in the United States of America its use has also been recommended for cardiovascular disease prevention. However, compliance has been found to be a problem, and rates of prescribing vary between general practitioners. AIM: This study set out to describe the prescribing of hormone replacement therapy in one general practice, to enable doctors to plan future prescribing and promotion of hormone replacement therapy, taking into account constraints on its use.
METHOD: The patient records of users of hormone replacement therapy were examined to collect data on menopausal status, reason for use, length of use, breaks from therapy and reasons for stopping therapy. Women with a history of hysterectomy and with risk factors for osteoporosis were identified from the practice morbidity register. Their use of hormone replacement therapy was recorded.
RESULTS: Of women aged 40-59 years on the practice list, 348 were taking hormone replacement therapy (20%). Of 107 women aged under 52 years who had had a hysterectomy and bilateral oophorectomy 76 were taking therapy (71%). Of 158 women under the age of 52 years who had had a hysterectomy with preservation of the ovaries 39 were taking therapy (25%). Among women taking hormone replacement therapy for the relief of menopausal symptoms, the highest rate of use was among those aged 50-54 years where 93 were on therapy (24% of women in that age group in the practice). Twenty out of 47 women with a recorded risk factor for osteoporosis were taking therapy. More than three quarters of women using hormone replacement therapy appeared to be taking it continuously.
CONCLUSION: The uptake of hormone replacement therapy was found to be high for women with a surgical menopause, the group most easily identifiable as at risk of osteoporosis. Women who decided to take therapy appeared to take it continuously, and therefore effectively for prevention. Rate of uptake, rather than compliance, is more likely to constrain its use in prevention.

Entities:  

Mesh:

Year:  1995        PMID: 7612339      PMCID: PMC1239297     

Source DB:  PubMed          Journal:  Br J Gen Pract        ISSN: 0960-1643            Impact factor:   5.386


  9 in total

Review 1.  Hormone therapy to prevent disease and prolong life in postmenopausal women.

Authors:  D Grady; S M Rubin; D B Petitti; C S Fox; D Black; B Ettinger; V L Ernster; S R Cummings
Journal:  Ann Intern Med       Date:  1992-12-15       Impact factor: 25.391

2.  Compliance with hormone replacement therapy (HRT) after screening for post menopausal osteoporosis.

Authors:  P J Ryan; R Harrison; G M Blake; I Fogelman
Journal:  Br J Obstet Gynaecol       Date:  1992-04

3.  Compliance with hormonal replacement therapy.

Authors:  B G Wren; L Brown
Journal:  Maturitas       Date:  1991-03       Impact factor: 4.342

4.  Use of oestrogen replacement therapy in high risk groups in the United Kingdom.

Authors:  T D Spector
Journal:  BMJ       Date:  1989-12-09

5.  Measuring the impact of menopausal symptoms on quality of life.

Authors:  E Daly; A Gray; D Barlow; K McPherson; M Roche; M Vessey
Journal:  BMJ       Date:  1993-10-02

Review 6.  Pathogenesis of climacteric complaints: ready for the change?

Authors:  A Oldenhave; C Netelenbos
Journal:  Lancet       Date:  1994-03-12       Impact factor: 79.321

7.  Primary non-compliance with prescribed medication in primary care.

Authors:  P H Beardon; M M McGilchrist; A D McKendrick; D G McDevitt; T M MacDonald
Journal:  BMJ       Date:  1993-10-02

8.  Can we improve compliance with long-term HRT?

Authors:  J Coope; J Marsh
Journal:  Maturitas       Date:  1992-10       Impact factor: 4.342

9.  The menopause and hormone replacement therapy: views of women in general practice receiving hormone replacement therapy.

Authors:  P J Roberts
Journal:  Br J Gen Pract       Date:  1991-10       Impact factor: 5.386

  9 in total
  8 in total

1.  Hormone replacement therapy: assessment of present use, costs, and trends.

Authors:  J Townsend
Journal:  Br J Gen Pract       Date:  1998-02       Impact factor: 5.386

2.  Women doctors' use of hormone replacement therapy. May be to enable them to cope with demands of their job.

Authors:  F Griffiths
Journal:  BMJ       Date:  1996-03-09

3.  Adequacy of hormone replacement therapy for osteoporosis prevention assessed by serum oestradiol measurement, and the degree of association with menopausal symptoms.

Authors:  M Rodgers; J E Miller
Journal:  Br J Gen Pract       Date:  1997-03       Impact factor: 5.386

4.  Prevalence and duration of postmenopausal hormone replacement therapy use in a managed care organization, 1990-1995.

Authors:  M T Connelly; M Richardson; R Platt
Journal:  J Gen Intern Med       Date:  2000-08       Impact factor: 5.128

5.  Menopausal hormone therapy and risk of biliary tract cancers.

Authors:  Sarah S Jackson; Ruth M Pfeiffer; Chiara Gabbi; Lesley Anderson; Shahinaz M Gadalla; Jill Koshiol
Journal:  Hepatology       Date:  2022-02       Impact factor: 17.298

6.  Women's use of hormone replacement therapy for disease prevention; results of a community survey.

Authors:  Karen Ballard
Journal:  Br J Gen Pract       Date:  2002-10       Impact factor: 5.386

7.  Ethnic differences in hormone replacement prescribing patterns.

Authors:  A F Brown; E J Pérez-Stable; E E Whitaker; S F Posner; M Alexander; J Gathe; A E Washington
Journal:  J Gen Intern Med       Date:  1999-11       Impact factor: 5.128

8.  Comparison of Bone Mineral Density among Alcoholism and Nonalcoholism Athlete and Nonathlete Subjects.

Authors:  Siros Hosseini; Roholla Valizade; Fateme Daraei Heydarabadi
Journal:  Euroasian J Hepatogastroenterol       Date:  2014-01-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.